Mill Creek, WA

Frontier Derm Partners

Psoriasis

Eczema

Dermatitis

Atopic Dermatitis

Apremilast

Rocatinlimab

Amgen

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Frontier Derm Partners | Mill Creek, WA

Site insights

Work at this site?

Active trials

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) (ROCKET-Ignite)

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Trial sponsors